NPHP1

Across TCGA pan-cancer cohorts, NPHP1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NPHP1 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher NPHP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPHP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

BRCA, UCEC, and PRAD are the cancer types where NPHP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.313	0.924	<.001	36	view →
UCEC	DFS	Median	All	0.975	0.826	.010	20	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.192	0.728	.007	3	view →
ACC	DFS	Median	All	0.112	0.544	.042	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NPHP1–BRCA (OS)

Open the BRCA breakdown →